Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Envelope vaccination shapes viral envelope evolution following simian immunodeficiency virus infection in rhesus monkeys.

Basavapathruni A, Yeh WW, Coffey RT, Whitney JB, Hraber PT, Giri A, Korber BT, Rao SS, Nabel GJ, Mascola JR, Seaman MS, Letvin NL.

J Virol. 2010 Jan;84(2):953-63. doi: 10.1128/JVI.01679-09.

2.

Transmitted/founder simian immunodeficiency virus envelope sequences in vesicular stomatitis and Semliki forest virus vector immunized rhesus macaques.

Gambhira R, Keele BF, Schell JB, Hunter MJ, Dufour JP, Montefiori DC, Tang H, Rose JK, Rose N, Marx PA.

PLoS One. 2014 Oct 31;9(10):e109678. doi: 10.1371/journal.pone.0109678.

3.

Vaccine protection against simian immunodeficiency virus in monkeys using recombinant gamma-2 herpesvirus.

Bilello JP, Manrique JM, Shin YC, Lauer W, Li W, Lifson JD, Mansfield KG, Johnson RP, Desrosiers RC.

J Virol. 2011 Dec;85(23):12708-20. doi: 10.1128/JVI.00865-11.

4.
5.

Breakthrough of SIV strain smE660 challenge in SIV strain mac239-vaccinated rhesus macaques despite potent autologous neutralizing antibody responses.

Burton SL, Kilgore KM, Smith SA, Reddy S, Hunter E, Robinson HL, Silvestri G, Amara RR, Derdeyn CA.

Proc Natl Acad Sci U S A. 2015 Aug 25;112(34):10780-5. doi: 10.1073/pnas.1509731112.

7.

Autologous neutralizing antibodies to the transmitted/founder viruses emerge late after simian immunodeficiency virus SIVmac251 infection of rhesus monkeys.

Yeh WW, Rahman I, Hraber P, Coffey RT, Nevidomskyte D, Giri A, Asmal M, Miljkovic S, Daniels M, Whitney JB, Keele BF, Hahn BH, Korber BT, Shaw GM, Seaman MS, Letvin NL.

J Virol. 2010 Jun;84(12):6018-32. doi: 10.1128/JVI.02741-09.

8.

Limited contribution of mucosal IgA to Simian immunodeficiency virus (SIV)-specific neutralizing antibody response and virus envelope evolution in breast milk of SIV-infected, lactating rhesus monkeys.

Permar SR, Wilks AB, Ehlinger EP, Kang HH, Mahlokozera T, Coffey RT, Carville A, Letvin NL, Seaman MS.

J Virol. 2010 Aug;84(16):8209-18. doi: 10.1128/JVI.00656-10.

9.

Envelope variable region 4 is the first target of neutralizing antibodies in early simian immunodeficiency virus mac251 infection of rhesus monkeys.

Yeh WW, Brassard LM, Miller CA, Basavapathruni A, Zhang J, Rao SS, Nabel GJ, Mascola JR, Letvin NL, Seaman MS.

J Virol. 2012 Jul;86(13):7052-9. doi: 10.1128/JVI.00107-12.

11.

Envelope-modified single-cycle simian immunodeficiency virus selectively enhances antibody responses and partially protects against repeated, low-dose vaginal challenge.

Alpert MD, Rahmberg AR, Neidermyer W, Ng SK, Carville A, Camp JV, Wilson RL, Piatak M Jr, Mansfield KG, Li W, Miller CJ, Lifson JD, Kozlowski PA, Evans DT.

J Virol. 2010 Oct;84(20):10748-64. doi: 10.1128/JVI.00945-10.

12.

Evolution of envelope-specific antibody responses in monkeys experimentally infected or immunized with simian immunodeficiency virus and its association with the development of protective immunity.

Cole KS, Rowles JL, Jagerski BA, Murphey-Corb M, Unangst T, Clements JE, Robinson J, Wyand MS, Desrosiers RC, Montelaro RC.

J Virol. 1997 Jul;71(7):5069-79.

14.

Incomplete protection, but suppression of virus burden, elicited by subunit simian immunodeficiency virus vaccines.

Israel ZR, Edmonson PF, Maul DH, O'Neil SP, Mossman SP, Thiriart C, Fabry L, Van Opstal O, Bruck C, Bex F, et al.

J Virol. 1994 Mar;68(3):1843-53.

15.

Comparative efficacy of recombinant modified vaccinia virus Ankara expressing simian immunodeficiency virus (SIV) Gag-Pol and/or Env in macaques challenged with pathogenic SIV.

Ourmanov I, Brown CR, Moss B, Carroll M, Wyatt L, Pletneva L, Goldstein S, Venzon D, Hirsch VM.

J Virol. 2000 Mar;74(6):2740-51.

16.
17.

Induction of mucosal protection against primary, heterologous simian immunodeficiency virus by a DNA vaccine.

Fuller DH, Rajakumar PA, Wilson LA, Trichel AM, Fuller JT, Shipley T, Wu MS, Weis K, Rinaldo CR, Haynes JR, Murphey-Corb M.

J Virol. 2002 Apr;76(7):3309-17.

18.
19.

Vectored Gag and Env but not Tat show efficacy against simian-human immunodeficiency virus 89.6P challenge in Mamu-A*01-negative rhesus monkeys.

Liang X, Casimiro DR, Schleif WA, Wang F, Davies ME, Zhang ZQ, Fu TM, Finnefrock AC, Handt L, Citron MP, Heidecker G, Tang A, Chen M, Wilson KA, Gabryelski L, McElhaugh M, Carella A, Moyer C, Huang L, Vitelli S, Patel D, Lin J, Emini EA, Shiver JW.

J Virol. 2005 Oct;79(19):12321-31.

20.

Significant protection against high-dose simian immunodeficiency virus challenge conferred by a new prime-boost vaccine regimen.

Schell JB, Rose NF, Bahl K, Diller K, Buonocore L, Hunter M, Marx PA, Gambhira R, Tang H, Montefiori DC, Johnson WE, Rose JK.

J Virol. 2011 Jun;85(12):5764-72. doi: 10.1128/JVI.00342-11.

Supplemental Content

Support Center